Dx Deals: Labcorp Acquires Stake in European Testing Giant
$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays
From - Laboratory Industry Report
As usual, the Big 3 of Abbott, Quest and LabCorp were the driving force of M&A activity in the diagnostics industry in the first half of 2017…
From - Laboratory Industry Report
The FDA made a stir in May by approving a cancer drug (Keytruda (pembrolizumab) PD-1/PD-L1 inhibitor from Merck) administered on the basis of a…
By Mike O'Brien bio
Here is my periodic update prepared for interested HR professionals trying to deal with the complex American employment laws…
From - Laboratory Industry Report
When it comes to measuring Dx product effectiveness, few things speak louder than the attitudes of ordering physicians. With that in mind…
From - Laboratory Industry Report
After a relatively slow March and April, business has picked up noticeably in May, June and July with deal volume increasing across all…
From - Laboratory Industry Report
Laboratory test products have been appearing on the shelves of mass retail stores with growing frequency. But the newly announced partnership between Walmart and Quest Diagnostics raises…
From - Laboratory Industry Report
Medicare contractors are slowly coming around on covering unproven molecular assays. The most notable new baby steps come from, Palmetto GBA (Columbia, SC), one of Medicare's most important contractors in the form of…
From - Laboratory Industry Report
The FDA budget pot continues to boil. In March, the Trump administration proposed a controversial provision to double the medical user fees that diagnostics, medical device and…